A Massachusetts General Hospital (MGH) research team has found how a variant in an important epigenetic enzyme – previously associated by population-based genetic studies with Crohn’s disease and other immune disorders – interferes with the action of the innate immune system, potentially upsetting the healthy balance between the microbial population of the gastrointestinal tract and the immune response. In their paper published in Science Immunology the team reports findings that SP140 – an epigenetic reader protein that plays a critical role in determining whether or not target genes are expressed – is essential to suppressing inappropriate gene expression in macrophages, innate immune cells that are critical to maintaining intestinal balance.
“More than 400 enzymes write, read or erase the epigenome, and mutations in these enzymes are some of the most prevalent perturbations in cancers, prompting rigorous efforts to identify compounds that could inhibit their function and reset gene expression,” says Kate Jeffrey, PhD, of the MGH Gastrointestinal Unit and the Center for the Study of Inflammatory Bowel Disease, corresponding author of the Science Immunology report. “Our knowledge of epigenomic enzyme mutations in immune-mediated disease is lagging well behind the cancer field, and our study – the first to examine the function of SP140 in any detail – shows how its loss in Crohn’s disease triggers intestinal inflammation.”
SP140 is predominantly expressed in immune cells, and a variant form of the gene has been associated with Crohn’s disease, multiple sclerosis and chronic lymphocytic leukemia. Prior to this study both the normal function of the SP140 protein and how the gene variant affected the protein and caused disease were unknown. In a series of experiments, Jeffrey’s team showed that the unaltered form of SP140 is required to maintain the appropriate expression of genes that define the identity and function of macrophages. The immune disorder variant – characterized by 17 individual sequence changes – resulted in a loss of SP140 protein that compromised the ability of macrophages to respond to microbial signals.
The researchers also showed that reducing SP140 expression in the immune cells of a mouse model of colitis increased intestinal inflammation. In addition, examining intestinal biopsy samples from a group of Crohn’s disease patients revealed that those in whom SP140 expression was reduced responded better to anti-TNF (tumor necrosis factor) therapy – a treatment for inflammatory conditions that is effective in only about half of Crohn’s patients – than did patients with typical SP140 levels.
“Finding this correlation between lower intestinal levels of SP140 and a better response to anti-TNF represents a potential precision medicine strategy for tailoring anti-TNF-like therapies to Crohn’s patients carrying the variant form of SP140,” says Jeffrey, who is an assistant professor of Medicine at Harvard Medical School. “Our study may also lead to better inflammatory bowel disease therapies by highlighting the critical role of epigenetic mechanisms for intestinal health. Although directly targeting SP140 would not be a good option, since its loss is detrimental to intestinal health, leveraging other epigenetic enzyme inhibitors that promote protective innate immune responses in the intestine could be a real therapeutic option”
Additional research is needed to better understand exactly how SP140 normally limits the expression of inappropriate genes and whether this function is limited to macrophages or also occurs in other SP140-expressing immune cells, Jeffrey notes. Her team also hopes to investigate the role of the Crohn’s-associated SP140 variant in multiple sclerosis and chronic lymphocytic leukemia, along with identifying other epigenetic enzymes that may be therapeutically targetable in inflammatory bowel disease and other immune-driven disorders.
Stuti Mehta, PhD, of the MGH Gastrointestinal Unit and the Center for the Study of Inflammatory Bowel Disease (CSIBD), is first author of the Science Immunology paper. Additional co-authors include Ramnik Xavier, MD, MGH Gastrointestinal Unit and CSIBD; Terry Means, PhD, MGH Division of Rheumatology, Allergy and Immunology; Cisca Wijmenga, PhD, University of Groningen, The Netherlands; and James Lee, MD, University of Cambridge School of Clinical Medicine in the U.K. Support for the study includes National Institutes of Health grants P30 DK043351 and R01 AI07087 and a grant from the Kenneth Rainin Foundation. Jeffrey is a Claflin Distinguished Scholar at the MGH.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America’s Best Hospitals."
Media contact: Noah Brown, email@example.com, (617) 643-3907